Clinical Management of Kidney Allograft Dysfunction

Rubin Zhang

Section of Nephrology, Department of Medicine, Tulane University School of Medicine, New Orleans, USA
Email: rzhang@tulane.edu

Received 28 February 2014; revised 28 March 2014; accepted 5 April 2014

Abstract

Allograft dysfunction is a common problem after kidney transplant. Allograft rejection is an important entity, and timely diagnosis and appropriate treatment are essential for caring transplant recipients. Hyperacute rejection is mediated by the preformed donor specific antibody, while accelerated acute rejection represents an anamnestic response by memory B and T cells. They occur early after transplant. Acute cellular rejection is relatively common and usually responds to pulse corticosteroids or antithymocyte globulin (ATG). The complexity of antibody-mediated rejection (AMR) as well as its detrimental effect has been increasingly recognized. The treatment of acute AMR requires a combination of several modalities, such as plasmapheresis or immunoadsorption, IVIG, corticosteroids, rituximab and ATG. After treatment of rejection episode, the maintenance immunosuppressive drugs should be adjusted to prevent further acute rejection and/or evolution into chronic active rejection. Chronic rejection is not reversible and it has been recognized as the most important cause of chronic graft dysfunction and failure.

Keywords

Acute Rejection, Cellular Rejection, Donor Specific Antibody, Antibody-Mediated Rejection, Chronic Rejection

1. Introduction

Kidney transplantation has become the preferred treatment for qualified patients with end stage of renal disease. Successful kidney transplant is more cost-effective than maintenance dialysis, and more importantly, it provides better quality of life and prolongs life [1]. Renal allograft dysfunction is a common and complex problem and appropriate management is critical for the long-term graft function and graft survival. The common causes of
acute graft dysfunction are summarized in Table 1. The clinical work-up is similar to acute kidney injury of native kidneys in both pre-renal and post-renal aspects. Additionally, there are several types of rejection that can occur in transplanted kidney, including hyperacute rejection, accelerated acute rejection, acute rejection and chronic active rejection [2]-[5]. The advance in transplant immunology provides us the insight into the complexity of antibody-mediated rejection as well as its detrimental effects on the graft function and survival. The process of allograft rejection may evolve from pre- and/or post-transplant sensitization, to acute rejection or subclinical rejection, to chronic active rejection and to eventual graft failure. This review will discuss the work-up of graft dysfunction and particularly will focus on the clinical diagnosis and management of acute rejection.

2. Hyperacute Rejection

Hyperacute rejection occurs immediately after transplant. It is mediated by the preformed donor specific antibody (DSA). DSA can be anti-HLA, anti-ABO or other non-HLA antibodies [2]-[5]. Hyperacute rejection results in an irreversible vascular rejection, intravascular thrombosis and graft necrosis. The graft is tender and does not make much urine. Renal scan shows no or little uptake, which is different from acute tubular necrosis. Surgical exploration and graft nephrectomy is indicated. The routine pretransplant crossmatch and verification of ABO compatibility between donor and recipient should prevent the majority of hyperacute rejection episodes [2].

3. Accelerated Acute Rejection

Accelerated acute rejection (or delayed hyperacute rejection) can occur within 24 hours to several days after transplant. It represents an anamnestic response by memory B and T cells from prior sensitization events, and may involve both humoral and cellular components. Even a negative crossmatch before transplant may not prevent the development of accelerated acute rejection, as the preformed DSA titer may be too low to be detected before kidney transplant [2].

4. Acute Rejection

Acute rejection can be either acute cellular rejection, antibody-mediated rejection or both. It is more common

<table>
<thead>
<tr>
<th>Table 1. Differential diagnosis of acute allograft dysfunction.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Pre-renal azotemia</td>
</tr>
<tr>
<td>Volume depletion (diuretics, poor intake, vomiting, diarrhea)</td>
</tr>
<tr>
<td>Vascular constriction (CNI toxicity, NSAID)</td>
</tr>
<tr>
<td>2. Intrinsic renal diseases</td>
</tr>
<tr>
<td>Arterial or venous stenosis, thrombosis or compression</td>
</tr>
<tr>
<td>ATN</td>
</tr>
<tr>
<td>Acute or accelerated acute rejection (cellular, humoral or both)</td>
</tr>
<tr>
<td>Pyelonephritis</td>
</tr>
<tr>
<td>Thrombotic microangiopathy (TMA)</td>
</tr>
<tr>
<td>Recurrent glomerular disease (FSGS, aHUS)</td>
</tr>
<tr>
<td>3. Post-renal obstruction</td>
</tr>
<tr>
<td>Foley catheter obstruction</td>
</tr>
<tr>
<td>Perinephris fluid collection (urine leak, hematoma, lymphocele)</td>
</tr>
<tr>
<td>Donor ureteral obstruction (kinking, stricture, blood clots)</td>
</tr>
<tr>
<td>Neurogenic bladder</td>
</tr>
<tr>
<td>Enlarged prostate (BPH, prostate cancer)</td>
</tr>
</tbody>
</table>
5. Acute Cellular Rejection

Acute cellular rejection (ACR) is diagnosed by histologic finding of T-lymphocyte infiltration in tubular—interstitial parenchyma (tubulitis) and vascular wall (arteritis). The Banff 2007 classification is the widely adopted pathohistological definition of different types/grades of ACR [4]. Pulse corticosteroid is the first-line therapy for ACR in most centers. Methylprednisolone, 3 to 5 mg/kg, is given intravenously for several (3 to 7) days. Mild or moderate ACR, such as Banff class borderline changes, 1A or 1B, usually responds well to steroid pulse therapy. After intravenous pulse steroids, oral steroids are given and then tapered to a maintenance dosage [8] [9]. The maintenance immunosuppressive drugs may also need to be adjusted to prevent further ACR episode.

Steroid-resistant ACR was traditionally defined as lack of improvement in renal function within 5 to 7 days of intravenous pulse steroids. We consider those with progressively decreasing urine output or worsening renal function despite of 2 days of pulse corticosteroids as steroid resistance. In these cases, we start polyclonal antithymocyte globulin (ATG) early. Also, severe ACR with vascular involvement, such as Banff class 2A or above, often needs ATG therapy, as pulse steroids alone may not provide complete resolution of vascular rejection or recovery of renal function [10] [11]. There are two forms of ATG, either ATGAM or thymoglobulin. A direct comparison between thymoglobulin and ATGAM was performed, and thymoglobulin resulted in a higher rate of reversal of rejection and a lower rate of recurrent ACR [10]. The typical dose of thymoglobulin is either 3 mg/kg per day for 3 days or 1.5 mg/kg per day for 5 days. The FDA approved total dose of thymoglobulin for treatment of steroid-resistant acute rejection is 10 mg/kg. ATG is associated with severe side effects. The cytokine release syndrome can be prevented by concurrent administration of steroids, acetaminophen and diphenhydramine. Antiviral and antimicrobial prophylaxis against CMV infection and pneumocystis carinii pneumonia are recommended after ATG therapy [10] [11]. The risk of developing post transplant lymphoproliferative disease should be kept in mind, and patients should be monitored for this complication. Repeat kidney biopsy is indicated in ACR that is resistant to steroids and/or ATG to rule out other pathology, such as concurrent acute tubular necrosis, antibody-mediated rejection, BKV nephropathy or chronic irreversible fibrosis. The underline chronic fibrosis can be masked by interstitial inflammation of ACR, and it usually becomes more recognizable on repeat biopsy after the treatment of ACR.

6. Antibody-Mediated Rejection

Antibody-mediated rejection (AMR) was historically presumed when biopsy revealed severe vascular rejection or when the rejection was not responsive to the conventional treatment of ACR. The advent of C4d staining, sensitive assay to detect DSA and the description of typical histologic findings of AMR have improved our recognition that rejection is often AMR, either alone or in conjunction with ACR [2]-[5] [12] [13]. The Banff 2013 classification of AMR has been recently published [5]. Clinical diagnosis of AMR is usually based on 3 of the 4 criteria: 1) graft dysfunction; 2) detection of DSA; 3) positive C4d staining in the peritubular capillaries (PTC); and 4) the characteristic histologic findings, such as peritubularcapillaritis, glomerulitis and arterial fibroid ne-
crosis. However, the risk of AMR is very high in pre-sensitized patients, such as HLA and/or ABO incompatible transplants after desensitization protocol, the husband to wife or the child to mother donation and the patients with known preformed DSA. In such high risk patients, AMR should be considered with fewer (2 of the 4) diagnostic criteria in the absence of another identifiable cause of graft dysfunction, so that treatment may be initiated without delay [14].

DSA testing should be performed during the workup of graft dysfunction when AMR is concerned. Routine screening for the development of de novo DSA may permit early detection of AMR in high risk patients [15]. C4d is a degradation product of the classic complement pathway. A unique feature of C4d is that it binds covalently to the endothelial basement membrane, thereby avoiding removal during tissue processing. C4d deposition in PTC serves as an immunologic footprint of AMR. It is in a linear pattern and best demonstrated by immunofluorescence in frozen tissue section [3] [4] [12] [16]. But some patients with AMR may not have both positive DSA and C4d staining. Cases with positive DSA but negative C4d staining may result from either technique error (false negative), non-complement activating DSA, or low level of DSA detected by highly sensitive assay without clinical relevance [4] [13]. In addition, the production of DSA precedes C4d deposition in the course of AMR, and a biopsy performed too early may not find the typical C4d deposition. Also, AMR can be caused by non-HLA antibodies. These may include hemagglutinin A or B antibody, anti-MICA, anti-minor histocompatibility antigens (MiHA), antiendothelial antibodies and anti-angiotensin-2 receptor [2] [17] [18]. As our knowledge in transplant immunology advances, there will likely be more alloreactive and autoreactive antibodies to be discovered in the future.

Treatment of AMR is often refractory to the treatment used for ACR. The optimal therapy for AMR remains to be defined, but it usually consists of a combination of several modalities, such as plasmapheresis or immunoadsorption, IVIG, corticosteroids, rituximab, ATG, bortezomib, eculizumab and occasionally splenectomy [3] [19]-[25]. Plasmapheresis or immunoadsorption with protein A removes the circulating DSA, but neither can suppress antibody production [3] [19] [24]. AMR associated with high circulating DSA titer usually justify plasmapheresis or immunoadsorption as a part of its treatment. IVIG is often administrated after plasmapheresis. Possible actions of IVIG include anti-idiotypic antibodies neutralizing DSA, inhibiting complement binding or activation and suppressing DSA synthesis [3] [21] [25]. Rituximab depletes B cells and it has been used to treat AMR [3] [20] [21]. Corticosteroids and ATG remain beneficial as they can control the B cell response by depleting or inhibiting the helper T cells. Bortezomib activates apoptosis of plasma cells, therefore directly decreases DSA production [3] [21] [22]. Eculizumab is now being reported in managing AMR, especially the severe ones refractory to the conventional therapy [3] [21] [26]. Splenectomy has also been reported as a rescue treatment in patients with severe AMR not responding to other treatments [23]. DSA should be quantified and the trends are monitored to guide clinical treatment. Repeat kidney biopsies are frequently needed to assess the success of treatment and to rule out other concurrent pathologic processes, especially in those not response to a reasonable course of treatment.

Acute rejection is a predictor of developing chronic rejection and/or transplant glomerulopathy [3] [27]. An increase in proteinuria after rejection is associated with poor graft outcome. Early diagnosed and completely reversed rejection after treatment may not affect long-term graft survival [28]. Whenever a rejection is diagnosed and treated, it is important to address the possibility of non-compliance or inadequate immunosuppression. The failure to correct the contributing factor may increase the risk of recurrent rejection and/ or development of chronic rejection. Patient noncompliance with medications may be caused by their inability to tolerate the side effects or by the financial difficulty to afford drugs. Inadequate immunosuppression may also be caused by adding new drug or herbal supplement that induces cytochrome P-450 enzyme and increases the metabolism of calcineurin inhibitors and/or mTOR inhibitors, which leads to decline in the drug trough level [21]. Rescue therapy for refractory rejection is commonly based upon the administration of tacrolimus and/or mycophenolate to those not receiving them as maintenance prior to rejection episode [29] [30]. Other rescue modalities that may be considered include alemtuzumab [31] [32] and graft radiation [33].

7. Subclinical Rejection

Subclinical rejection is usually defined as histological evidence of acute rejection by protocol biopsies, but clinically patients have normal or stable graft function [34] [35]. Untreated subclinical rejection may be a precursor to chronic rejection [35]. However, treatment of subclinical rejection may not consistently prevent chronic rejec-
tion and fibrosis lesions. It remains controversial whether protocol biopsy to diagnose subclinical rejection is necessary in all transplant patients. In many cases, it is difficult to separate a subclinical rejection from a normal graft accommodation. Therefore, protocol biopsy probably should be limited to high risk patients at current clinical practice [34] [36].

8. Chronic Active AMR

Chronic active AMR is diagnosed by combination of the typical chronic changes from biopsy (glomerular double counters, multilayering of PTC basement membrane, interstitial fibrosis/tubular atrophy (IF/TA), fibrous intimal thickening in arteries) and ongoing humoral activity (positive DSA, C4d staining in PTC, capillaritis) [3]-[5]. It is usually irreversible and there is no effective intervention for it [3] [37]. Theoretical treatment may include rituximab and/or IVIG to “control” the humoral activity or DSA level. The maintenance immunosuppressive drugs may be also increased or adjusted with more potent ones wishfully to “stabilize” the graft function. A recent study of rituximab combined with triple maintenance of steroids, mycophenolate and calcineurin inhibitors provided encouraging results. Compared to the control group, rituximab group had partial therapeutic response and an improvement in medial renal graft survival [38]. Clearly, large clinical trials are needed to address this important issue.

9. Chronic Allograft Dysfunction

Chronic allograft dysfunction is a slow, progressive loss of renal function one or more years after kidney transplant, which was previously referred as chronic allograft nephropathy and now as interstitial fibrosis and tubular atrophy (IF/TA) in Banff classification [1]-[5]. Clinically, it is usually diagnosed by a slowly rising serum creatinine level, increasing proteinuria and worsening hypertension. IF/TA represents a complex process culminating immunological and non-immunological injuries. It is the second most common cause of graft loss after the leading cause, death with a functioning graft. Optimal treatment of IF/TA remains unknown. Other causes of chronic allograft dysfunction are summarized in Table 2. When a specific cause of graft dysfunction is identified, then appropriate treatment may improve or stabilize the graft function.

10. New Biomarkers

In addition to immunological risk analysis and screening for DSA, kidney biopsy is usually necessary for diagnosing allograft rejection. There has been great interest in searching for non-invasive biomarkers to predict acute rejection [39]-[44]. Several urine proteomics and biomarkers have been reported, such as CXCL9, CXCL 10, mRNA levels of granzyme B, perforin, TIM-3, FOXP3 and others [39]-[42]. Enhanced expression of perforin, granzyme B, Fas ligand, HLA class-1 antigens in peripheral blood leukocytes or tissue have been linked to rejection [43]-[45]. Recently, a three-gene signature of CD3ε mRNA, IP-10 mRNA and 18S rRNA levels in urinary

<table>
<thead>
<tr>
<th>Table 2. Differential diagnosis of chronic allograft dysfunction.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Immunological causes</strong></td>
</tr>
<tr>
<td>Chronic active rejection (cellular, humoral or both)</td>
</tr>
<tr>
<td>Chronic rejection (cellular, humoral or both)</td>
</tr>
<tr>
<td><strong>2. Non-immunological causes</strong></td>
</tr>
<tr>
<td>Chronic CNI toxicity</td>
</tr>
<tr>
<td>Infection (BKV nephropathy, chronic pyonephritis)</td>
</tr>
<tr>
<td>Chronic obstruction/ hydronephrosis</td>
</tr>
<tr>
<td>Recurrent or de novo glomerular diseases</td>
</tr>
<tr>
<td>Recurrent or de novo diabetic nephropathy</td>
</tr>
<tr>
<td>Hypertensive nephrosclerosis</td>
</tr>
<tr>
<td>Renal artery stenosis</td>
</tr>
</tbody>
</table>
cells has been reported to be diagnostic and prognostic of acute cellular rejection in kidney transplant grafts [46]. Current available information remains inconclusive and better designed multicenter studies are required to validate these “rejection–specific” biomarkers for clinical practice [45].

11. Conclusion

Allograft rejection is an important and unique problem of graft dysfunction after kidney transplant. Hyperacute rejection is mediated by the preformed DSA, while accelerated acute rejection represents an anamnestic response by memory B and T cells due to prior sensitization. They occur early after transplant and may not be reversible. ACR is relatively more common and usually responds to pulse corticosteroids with or without ATG. The complexity of AMR as well as its detrimental effect has been increasingly recognized. The treatment acute AMR requires a combination of several modalities, such as plasmapheresis or immunoadsorption, IVIG, corticosteroids, rituximab and ATG. After successful treatment of acute rejection, the maintenance immunosuppressive drugs should be adjusted to prevent further acute rejection and/or evolution into chronic active rejection. Chronic rejection is usually not reversible and it has been recognized as the most important cause of chronic graft dysfunction and eventual graft failure.

References


